New arguments for double action release active drugs in preparation for vaccination against pneumococcus among children with chronic sites of infection in nasopharynx

Abstract

Aim: To evaluate the results of the prospective comparative study on efficacy of use of Anaferon for children in preparation for vaccination against pneumococcus among 994 children (aged from 2 to 5 years) with chronic nasopharyngeal diseases.

Materials: The study period: December 2011 to April 2015. Presents a comparative analysis of the incidence rate of respiratory and ENT-infections. In addition, the total number of cell elements and the main cell population ratio were analyzed, lysozyme activity and secretory immunoglobulin A (slgA) in nasal secretions were evaluated.

Results: It was shown that use of Anaferon for children during a 1 month period beginning 10 days prior to vaccination increases vaccination coverage among children. The group taking Anaferon for children showed that over a year period the incidence rate of acute respiratory infection was 1.2 times less (p <0,022), pneumonia — 1.4 times less (p =0,354), acute bronchitis —1.2 times less (p =0,374), acute otitis media and chronic maxillary sinusitis — 1.2 (p =0,467) and 1.5 times less (p =0,279) than in the control group. The vaccination and release active drugs also showed a positive impact on the local protective factors of the upper respiratory tract such as lysozyme, slgA, cell elements of nasal secretions.

Conclusions: The study showed good tolerability of Anaferon for children and PCV13, safety of its use among children with chronic nasopharyngeal diseases.